PT Itama Ranoraya Tbk (IRRA) recorded a significant sales growth in the first five months of this year, around 366% YoY or Rp331 billion compared to the same period last year of only Rp71.02 billion.

"We are optimistic that this year's growth target of around 80-100% can be achieved again," said Itama's President Director, Heru Firdausi Syarif, in his statement, on Wednesday (23/6).

According to Heru, in vitro products in antigen tests are still the most significant contributor to the company's sales, followed by other Abbotts, such as Reagents and Plasma Machines, Terumo.

In the first semester of this year, sales were dominated by the retail segment and boosted growth significantly.

"This year, the company has begun to strengthen the retail or non-government segments to further enlarge the product market share, and diversify a more solid customer segment. Because, the previous year the sales portion from government